Soufflé gets $135M for three RNA medicines

Soufflé Therapeutics raises a $135M Series B led by Juvia Group to push siRNA drugs for FSHD and heart failure into the clinic. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…

Kyle LaHucik · 2026-10-13

A Bob Langer-affiliated startup has collected a megaround to advance at least three experimental oligonucleotide medicines. Soufflé Therapeutics uncorked a fresh $135 million in VC backing on Tuesday. The capital will ...

Source: Endpoints News